Header Logo

Connection

JAFFER A AJANI to Biomarkers, Tumor

Back to Details
This is a "connection" page, showing publications JAFFER A AJANI has written about Biomarkers, Tumor.
JAFFER A AJANI
Connection Strength
2.820
Biomarkers, Tumor
  1. Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification. Oncology. 2020; 98(12):884-888.
    View in: PubMed
    Score: 0.199
  2. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer. 2019 10 10; 18(1):141.
    View in: PubMed
    Score: 0.186
  3. Cancer stem cells in esophageal cancer and response to therapy. Cancer. 2018 10 15; 124(20):3962-3964.
    View in: PubMed
    Score: 0.174
  4. Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors. Br J Cancer. 2018 01; 118(1):52-61.
    View in: PubMed
    Score: 0.163
  5. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017 Feb; 35(4):446-464.
    View in: PubMed
    Score: 0.152
  6. Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. Am Soc Clin Oncol Educ Book. 2016; 35:104-11.
    View in: PubMed
    Score: 0.143
  7. Molecular biomarkers in gastric cancer. J Natl Compr Canc Netw. 2015 Apr; 13(4):e19-29.
    View in: PubMed
    Score: 0.136
  8. Many a mickle makes a muckle. Translating a gastric cancer phenotype into a bigger thing. Onkologie. 2011; 34(10):499-500.
    View in: PubMed
    Score: 0.106
  9. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. Biomark Med. 2010 Aug; 4(4):535-41.
    View in: PubMed
    Score: 0.098
  10. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci. 2010 Apr; 55(4):1098-105.
    View in: PubMed
    Score: 0.090
  11. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev. 2007 Jun; 16(6):1200-5.
    View in: PubMed
    Score: 0.079
  12. Molecular mechanisms in Barrett's metaplasia and its progression. Semin Oncol. 2007 Apr; 34(2 Suppl 1):S2-6.
    View in: PubMed
    Score: 0.078
  13. Biomarkers of response to preoperative chemoradiation in esophageal cancers. Semin Oncol. 2006 Dec; 33(6 Suppl 11):S2-5.
    View in: PubMed
    Score: 0.076
  14. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther. 2006 Nov; 5(11):2844-50.
    View in: PubMed
    Score: 0.076
  15. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006 Aug 10; 24(23):3789-98.
    View in: PubMed
    Score: 0.074
  16. PD-L1 expression and overall survival in Asian and western patients with gastric cancer. Future Oncol. 2022 Jul; 18(21):2623-2634.
    View in: PubMed
    Score: 0.056
  17. Genome-wide host methylation profiling of anal and cervical carcinoma. PLoS One. 2021; 16(12):e0260857.
    View in: PubMed
    Score: 0.054
  18. Long non-coding RNAs are significantly associated with prognosis and response to therapies in gastric cancer. Clin Transl Med. 2021 06; 11(6):e421.
    View in: PubMed
    Score: 0.052
  19. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. Eur J Cancer. 2020 03; 127:150-157.
    View in: PubMed
    Score: 0.048
  20. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cancer. 2020 01; 23(1):95-104.
    View in: PubMed
    Score: 0.046
  21. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer. Gastric Cancer. 2019 07; 22(4):803-816.
    View in: PubMed
    Score: 0.044
  22. Serum miR-331-3p predicts tumor recurrence in esophageal adenocarcinoma. Sci Rep. 2018 09 18; 8(1):14006.
    View in: PubMed
    Score: 0.043
  23. Liquid biopsies in gastrointestinal malignancies: when is the big day? Expert Rev Anticancer Ther. 2018 01; 18(1):19-38.
    View in: PubMed
    Score: 0.041
  24. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer. 2017 Aug 22; 117(5):648-655.
    View in: PubMed
    Score: 0.040
  25. Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. Med Oncol. 2017 Aug; 34(8):135.
    View in: PubMed
    Score: 0.040
  26. D-mannose: a novel prognostic biomarker for patients with esophageal adenocarcinoma. Carcinogenesis. 2017 02 01; 38(2):162-167.
    View in: PubMed
    Score: 0.039
  27. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016 Dec; 140(12):1345-1363.
    View in: PubMed
    Score: 0.038
  28. Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Rev Gastroenterol Hepatol. 2016; 10(3):383-92.
    View in: PubMed
    Score: 0.036
  29. Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling. Clin Gastroenterol Hepatol. 2015 Oct; 13(10):1730-1737.e9.
    View in: PubMed
    Score: 0.034
  30. Cancer stem cells: the promise and the potential. Semin Oncol. 2015 Apr; 42 Suppl 1:S3-17.
    View in: PubMed
    Score: 0.034
  31. A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. Cancer. 2014 Dec 01; 120(23):3635-41.
    View in: PubMed
    Score: 0.032
  32. The role of microRNAs in cancers of the upper gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2013 Feb; 10(2):109-18.
    View in: PubMed
    Score: 0.029
  33. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011 Aug; 141(2):476-85, 485.e1-11.
    View in: PubMed
    Score: 0.026
  34. Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res. 2011 Apr 01; 17(7):1850-7.
    View in: PubMed
    Score: 0.026
  35. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One. 2010 Nov 30; 5(11):e15074.
    View in: PubMed
    Score: 0.025
  36. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. Mod Pathol. 2009 Dec; 22(12):1612-21.
    View in: PubMed
    Score: 0.023
  37. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol. 2007 Feb 20; 25(6):698-707.
    View in: PubMed
    Score: 0.019
  38. [Expression of transcription factor Sp1 in human gastric cancer tissue and its correlation with prognosis]. Zhonghua Zhong Liu Za Zhi. 2007 Feb; 29(2):107-11.
    View in: PubMed
    Score: 0.019
  39. Impact of cyclin D1 A870G polymorphism in esophageal adenocarcinoma tumorigenesis. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S11-5.
    View in: PubMed
    Score: 0.018
  40. Discordance of HER2 Expression and/or Amplification on Repeat Testing. Mol Cancer Ther. 2023 Aug 01; 22(8):976-984.
    View in: PubMed
    Score: 0.015
  41. Carcinoid--a comprehensive review. Acta Oncol. 2003; 42(7):672-92.
    View in: PubMed
    Score: 0.015
  42. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021 09 23; 12(1):5606.
    View in: PubMed
    Score: 0.013
  43. Drug resistance and Cancer stem cells. Cell Commun Signal. 2021 02 15; 19(1):19.
    View in: PubMed
    Score: 0.013
  44. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clin Cancer Res. 2021 03 15; 27(6):1663-1670.
    View in: PubMed
    Score: 0.013
  45. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009 Jul; 7(7):712-47.
    View in: PubMed
    Score: 0.011
  46. The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors. Gastric Cancer. 2019 11; 22(6):1100-1108.
    View in: PubMed
    Score: 0.011
  47. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018 01; 7(1):123-133.
    View in: PubMed
    Score: 0.010
  48. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer. 2016 10 11; 115(8):974-982.
    View in: PubMed
    Score: 0.009
  49. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut. 2013 Aug; 62(8):1100-11.
    View in: PubMed
    Score: 0.007
  50. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007 Feb 15; 109(4):658-67.
    View in: PubMed
    Score: 0.005
  51. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res. 2007 Feb 01; 13(3):912-9.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.